Table 2. Major AE profiles of ARSI and taxane.
Agent | Abiraterone | Enzalutamide | Apalutamide | Darolutamide | Docetaxel | Cabazitaxel |
---|---|---|---|---|---|---|
Major AEs | Fluid retention | Fall/Fracture | Fall/Fracture | Fatigue | Alopecia | Diarrhea |
Hepatic disorders | Fatigue | Fatigue | Change in taste | Fatigue | ||
Hypertension | Hot flashes | Hypothyroidism | Diarrhea | Infection | ||
Hypokalemia | Hypertension | Rash | Fatigue | Neutropenia | ||
Nail changes | ||||||
Neutropenia | ||||||
Peripheral edema | ||||||
Sensory neuropathy | ||||||
Stomatitis | ||||||
Clinical trial | COU-AA-301 [5] | AFFIRM [7] | TITAN [21] | ARAMIS [28] | TAX 327 [3] | TROPIC [9] |
COU-AA-302 [6] | PREVAIL [8] | SPARTAN [26] | CHAARTED [19] | CARD [12] | ||
LATITUDE [20] | ENZAMET [22] | |||||
STAMPEDE [38] | ARCHES [23] | |||||
PROSPER [27] |
AE: adverse event, ARSI: androgen receptor-signaling inhibitor.